(12-287) Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor (PCSK9i) Prescribing Practices for Patients with Clinical Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein (LDL)
Wednesday, December 6, 2023
2:00 PM – 3:00 PM
Location: Hall E, Lower Level
Co-Author(s): Alison Walck, Sarah Knauer, Colleen Strouse, Sarah Tucker
